PGEN - Precigen stock rises 13% on FDA fast track status for PRGN-3006 to treat blood cancer

The U.S. Food and Drug Administration granted fast track designation to Precigen's (NASDAQ:PGEN) PRGN-3006 to treat patients with relapsed or refractory acute myeloid leukemia, a cancer of the blood and bone marrow. The company said PRGN-3006 UltraCAR-T is a multigenic autologous chimeric antigen receptor (CAR)-T cell treatment. The company noted that PRGN-3006 UltraCAR-T has shown a favorable safety profile to date with no dose-limiting toxicities  or neurotoxicity, and has demonstrated dose-dependent in vivo expansion and durable persistence. PGEN +13.22% to $2.57 premarket April 4

For further details see:

Precigen stock rises 13% on FDA fast track status for PRGN-3006 to treat blood cancer